Corporate Newsletter

Thought leaders from around the country will provide an interactive discussion on the future of precision medicine and oncology through the use of big data.

Explore the Intersection of Big Data, Precision Medicine and Oncology on Nov. 29

  • Wed Nov 08 18:00:00 GMT 2017
  • California
  • Author Ashleigh Farver

Biocom invites you to join us for our 2nd Annual Big Data Executive Summit on Wednesday, November 29th at The Alexandria at Torrey Pines. This one-day event will feature illuminating discussions focused specifically on the intersection of big data, precision medicine and oncology. The program will include dynamic keynote presentations, panel discussions, and interactive use-case sessions with local industry leaders offering practical ways to make the strategic and technological decisions critical to Big Data success. Best-in-class technology partners will also be on hand to demo technology and services. This event is a great opportunity for company executives and senior management involved in both the strategy, application and technological decision making affecting Big Data programs.

Stephanie Devaney, NIH to Provide Opening Keynote During Big Data Summit
Stephanie Devaney, Deputy Director, All of Us Research Program, National Institutes of Health, will provide an update of the implementation of the Precision Medicine Initiative (PMI), a federal, inter-agency effort to accelerate the research and development of personalized therapies for patients. Devaney will also provide an update on the All of Us Research program, a historic research undertaking part of PMI, which will create a national, patient-powered cohort of one million or more Americans who will volunteer to participate in research throughout their lives and help unlock our understanding of diseases.

John Mattison, Kaiser Permanente to Provide Closing Keynote
When asked, “What’s the big idea or challenge you are thinking about as it relates to big data, precision medicine and the oncology space, our keynote speaker replied, “As genomics, microbiomics, and personal sensing IOT mature, we will discover preventive measures that are increasingly specific and relevant to each individual. The big opportunity will be to discover inexpensive unobtrusive wearables matched with machine learning to personalize the advice for health, wellness, early detection, and prevention for each individual. Some individuals will need intense monitoring for early detection of one form of cancer where their risk is high, while they may need no monitoring whatsoever for other forms of cancer. These monitoring methods will be personalized to the risk profiles of each individual. The promise of this approach will follow a typical exponential pathway, where the evidence basis for what works may be meager today, but will soon arrive at the same abundance that characterizes every other exponential science and technology.”

Our full line-up of confirmed speakers and panellists:

  • Dawn Barry, Vice President, Applied Genomics, Illumina
  • Indo Chakravarky, CEO, Navican
  • Stephanie Devaney, Deputy Director, All of Us Research Program, National Institutes of Health
  • Ahmed Ghouri, M.D., Founder and CEO, Interpreta
  • Jackson He, Senior Director of Strategic Planning, Intel Artificial Intelligence Product Group (AIPG), Intel Corporation
  • Patrick Lilley, Chief Data Scientist, Liquid Biosciences
  • John Mattison, Asst. Med. Director, Chief Health Information Officer, Kaiser Permanente
  • Mike Norman, Director, San Diego Supercomputer Center
  • Chris Orlando, Co-Founder, ScaleMatrix
  • Gunaretnam Rejagopal, VP, Global Head, Computational Sciences, Discovery Sciences, Janssen
  • Stephane Richard, President & COO, CureMatch
  • Corina Shtir, Head of Precision Medicine, Thermo Fisher Scientific 
  • David Wellis, CEO, San Diego Blood Bank
  • David Wetherelt, Business Development, 3M Health Information Systems

To learn more and register, click here.


Stay in the know with the Biocommunique

Sign up for Biocom's bi-weekly newsletter to get all the latest life science news sent directly to your inbox.


Related Articles View All  
The tour is conveniently following BIO-Europe and the only cost to Biocom members is airfare and hotel accommodations.  
Orphan drug tax credit, business expensing, tax brackets, and estate tax among list of differences to be worked through Senate and House by end of the year.  
Secure meeting space, network with individuals from other top biotech state organizations, and hear from up-and-coming life science companies.  
Protect NIH funding for biomedical research and urge Congress to permanently repeal the medical device tax.